---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044022"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:09:00.360001+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $45K convertible note with 35% discount conversion

## Summary
- Principal $45,000; maturity Sept 15, 2024; interest 8% (22% default); issued to 1800 Diagonal Lending LLC.
- Conversion price at 35% discount to avg of lowest 3 trading prices over 10 days prior; 4.99% beneficial ownership cap.
- Company may prepay within 180 days at escalating premiums: 110% to 129% of principal plus interest.
- Proceeds for general working capital; company also pays $5,000 buyer's legal/due diligence fees.
- Note issued under Section 4(a)(2)/Reg D private placement exemption.

## SEC filing metadata
- accession: 0001493152-23-044022
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223044022/0001493152-23-044022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223044022/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044022
- JSON: https://secwatch.observer/filing/0001493152-23-044022.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044022.txt

## Key facts
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $45,000 (effective 2023-12-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor
  - Value: $45,000
  - Effective: 2023-12-04
  source text: Effective December 4, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $45,000 (the “Note”), for a purchase price of $45,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223044022/0001493152-23-044022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.